{
    "comments": "Bimagrumab is an investigational monoclonal antibody that binds to activin type II A and B receptors to block activin and myostatin signalling in muscles and adipose tissue. It was originally intended to combat age-related muscle loss and other muscle-wasting conditions. Most recently it has been repositioned as a counter measure for the muscle loss in patients using GLP-1 agonist anti-obesity drugs such as <Ligand id=9724/> and <Ligand id=11429/>.",
    "bioactivityComments": "Bimagrumab inhibits myostatin binding to ACVR2B, thereby blocking myostatin-induced signalling as measured by a Smad dependent reporter gene assay <Reference id=26666/>.",
    "clinicalUse": "Bimagrumab is a clinical candidate that is under clinical investigation.",
    "mechanismOfAction": "Bimagrumab primarily targets the type II activin receptor ACVR2B <Reference id=26666/>, which is a type II receptor serine/threonine kinase. The antibody also has high affinity for ACVR2A, but this is much lower in comparison to ACVR2B binding.<br>This action blocks myostatin-induced SMAD pathway signalling, which is hypothesised to improve the formation of skeletal muscle <Reference id=26667/><Reference id=26668/>.",
    "absorptionAndDistribution": "",
    "metabolism": "",
    "elimination": "",
    "populationPharmacokinetics": "",
    "organFunctionImpairment": "",
    "immuno": "",
    "gtmp": ""
}